The goal of this clinical trial is to explore the efficacy and safety of denosumab in combination with tislelizumab and chemotherapy in the second-line treatment of immuno-experienced patients with EGFR/ALK/ROS1-negative advanced NSCLC.
Primary endpoint:
progression-free survival (PFS) assessed by investigators according to RECIST 1.1;
Secondary endpoint:
1. Overall survival (OS) assessed by investigators according to RECIST 1.1;
2. Objective response rate (ORR) assessed by investigators according to RECIST 1.1;
3. Disease control rate (DCR) assessed by investigators according to RECIST 1.1;
4. Duration of response (DOR) assessed by investigators according to RECIST 1.1;
Exploratory endpoint:
bone metastasis-free survival.
Participants will receive denosumab combined with tislelizumab and docetaxel.